October 31-November 4,  Protein & Antibody Engineering Summit in Lisbon

Harbour Antibodies Announces 25th License to Its Transgenic Mouse Platforms for Next Generation Monoclonal Antibody Discovery  Licenses Highlight Increasing Recognition of Platforms’ Potential   Rotterdam, The Netherlands and Cambridge, MA, September 18, 2015 – Harbour Antibodies BV today announced the signing of five new licenses to the company’s patented transgenic mouse platforms to discover next generation, high affinity, therapeutic human antibody products. These new licenses bring to 25 the total number of licenses by pharma and biotech companies, as well as academic organizations. The recent group of licensees includes MD Anderson Cancer Center and several international biotech companies and includes licenses to Harbour’s heavy chain only and conventional antibody generating …

PEGS: The Essential Protein Engineering Summit 2015, May 4-8, 2015 Boston, MA http://www.pegsummit.com Seaport World Trade Center

Harbour Antibodies Announces First U.S. Patent for Novel Transgenic Mouse Antibody Technology for Next Generation Therapeutic Antibody Discovery Patent Covering “Heavy Chain Only” Antibody Platform Enables Discovery of Products Not Achievable with Conventional Antibody Platforms Cambridge, MA, December 19, 2014 – Harbour Antibodies BV, announced the issuance of the first U.S. Patent (No. 8,883,150) covering the company’s HCAb mouse platform for producing human “heavy chain only” antibody molecules. The antibody molecules produced by the technology have broad potential for use by Harbour’s licensees to develop products with attributes not achievable by conventional antibody platforms. “Our HCAb mouse platform is a powerful technology for generating multiple diverse heavy-chain only antibody molecules …